This feature has been sponsored by Adaptive Biotechnologies The company has had influence on the development of this content
Understanding MRD in myeloma and ALL
Katja Weisel, MD, from University Hospital Tubingen, Tubingen, Germany explains the concept of MRD and its importance as a parameter when evaluating clinical response. As novel therapies that produce deep clinical responses are being prescribed for lymphoid malignancies, new ways to measure disease outcomes are needed.
Measuring MRD: NGS vs. flow cytometry
Prof. Weisel discusses the similarities and differences between using NGS and flow cytometry, the two predominant methods of measuring MRD. Both methods involve obtaining a bone marrow sample. Among the main differences between the two methods are the sensitivity and the intrinsically standardized nature of NGS-based MRD assays compared with flow cytometry.